×

Biotech and Pharmaceuticals Life Sciences

  • Hello, what a better night's sleep?

    James Proud, Hello founder & CEO talks about a tech device that monitors and improves sleep.

  • *British company licenses two COPD drugs from AstraZeneca. LONDON, March 17- Britain's Circassia has secured the U.S. rights from AstraZeneca for two drugs to treat chronic obstructive pulmonary disease, a progressive lung condition affecting millions of people, for up to $230 million. Circassia's Chief Executive Steve Harris said Tudorza, a bronchodilator...

  • "The persistence of vaccine-induced immunity to one year post-immunisation is truly impressive," said researcher Matthew Snape of the University of Oxford. That is different from another Ebola vaccine from Merck, which was the first to prove effective in preventing human infection during a large trial in Guinea last year. Scientists have been racing to...

  • March 9- INTERVIEW-NOVO NORDISK'S CEO SAYS LOOKING FOR DEALS TO BROADEN GROWTH OPPORTUNITIES NOVO NORDISK'S CEO SAYS ANY ACQUISITIONS LIKELY TO BE "LOW SINGLE-DIGIT BILLIONS OF DOLLARS". Novo Nordisk's new chief executive is looking at making acquisitions to broaden the Danish drugmaker's product line-up, in a change of tack that reflects a need for fresh...

  • March 7- Shares of U.S. pharmaceutical and biotechnology companies fell on Tuesday after President Donald Trump said he was working on a "new system" to reduce prices in the industry, without providing details of his plan. "Im skeptical about what it is that he might do that would actually have a material impact on drug prices," said Paul Heldman, managing partner at...

  • PARIS, March 6- Sanofi has struggled with a reputation as a laggard in finding new drugs but its global research chief believes the imminent approval of a game-changing eczema medicine signals a new era for the French company. Dupilumab has impressed doctors in a series of clinical trials over the past year and is widely expected to win a U.S. green light by the...

  • ZURICH, March 1- Novartis is making progress in its bid to catch rivals developing drugs that harness the immune system to fight cancer, one of its top research scientists and latest recruit from Harvard University told Reuters in an interview. Peter Hammerman joined the Swiss firm in late 2016, becoming the fourth leading cancer scientist to be poached in...

  • *270 mln euros to be invested. PARIS, Feb 27- French drugmaker Sanofi and Swiss manufacturer Lonza will invest 270 million euros in a new large-scale biologics facility that will produce monoclonal antibodies by 2020, the two companies said on Monday. Pending regulatory approvals, the facility- which will be established through a 50-50 joint venture- will be...

  • Feb 21- Drugmaker Bristol-Myers Squibb Co said on Tuesday it appointed three directors to its board in an agreement with JANA Partners LLC, an activist investor holding less than 1 percent of the company's stock. The stock fell 1.8 percent to $53.59 on Tuesday. New York- based JANA owned 3.9 million shares of Bristol-Myers as of Dec. 31, a $226 million stake well...

  • Feb 8- U.S. biopharmaceutical company Tesaro Inc is discussing its options with investment banks after receiving acquisition interest from several drugmakers, according to people familiar with the matter. Tesaro shares rose as much as 17 percent on the news and were up 11 percent at $180.50 in late morning trading in New York on Wednesday, giving the company a...

  • Feb 8- U.S. biopharmaceutical company Tesaro Inc is discussing its options with investment banks after receiving acquisition interest from several drug makers, according to people familiar with the matter. Tesaro is not actively exploring a sale, the people said this week, noting that there is a significant gap over the company's valuation between Tesaro and...

  • Songjiang Wang, who Cambridge, Massachusetts- based Merrimack has employed as director of statistical programming since 2011, was charged with conspiring to commit securities fraud in a criminal complaint filed in federal court in Boston. He was arrested after prosecutors brought related charges in June against Schultz Chan, who had been the director of...

  • Feb 2- The U.S. Food and Drug Administration on Thursday expanded the use of Bristol-Myers Squibb Co's Opdivo to include treatment of urothelial carcinoma, the most common type of bladder cancer. Investors were disappointed last month when Bristol-Myers said it would not seek accelerated FDA approval for a combination of Opdivo and another immunotherapy,...

  • *Q4 core EPS $1.21 vs consensus forecast $1.13. LONDON, Feb 2- AstraZeneca warned on Thursday that profit and revenue would both fall this year as cheap generic versions of its cholesterol drug Crestor continue to hit sales. Chief Executive Pascal Soriot reaffirmed his confidence in the trial, despite recent mixed developments in the hotly contested cancer...

  • *Qtrly Prevnar sales fall 23 pct to $1.42 bln. Jan 31- Pfizer Inc, which closed its $14 billion acquisition of Medivation Inc in September, reported a lower-than-expected profit, hit by lower demand for its flagship vaccine Prevnar and higher expenses. Pfizer earned an adjusted profit of 47 cents per share, missing the average analysts' estimate of 50 cents,...

  • Biotech is a critical business

    Joel Marcus, Alexandria Real Estate equities, talks about the immigration ban, and the benefits of tax repatriation from the biotech industry.

  • Jan 26- Bristol-Myers Squibb Co on Thursday posted a fourth-quarter profit that fell short of Wall Street estimates and lowered its 2017 earnings forecast amid tempered expectations for its key Opdivo immuno-oncology drug. For full-year 2017, the U.S. drugmaker cut its adjusted earnings per share outlook by 15 cents to between $2.70 and $2.90.

  • Jan 26- Bristol-Myers Squibb Co on Thursday posted fourth-quarter profits that fell short of Wall Street estimates and lowered its 2017 earnings forecast amid tempered expectations for its key Opdivo immuno-oncology drug. For full-year 2017, the U.S. drugmaker said it now expects adjusted earnings of $2.70 to $2.90 per share, down from its previous range of...

  • Jan 26- Bristol-Myers Squibb Co on Thursday reported fourth-quarter profit that fell short of Wall Street estimates and lowered its 2017 earnings forecast amid tempered expectations for its key Opdivo immuno-oncology drug. For full-year 2017, the U.S. drugmaker said it now expects adjusted earnings of $2.70 to $2.90 per share, down from its previous range...

  • Jan 25- Novartis, lagging some other big drugmakers in the first wave of immunotherapy drugs that are revolutionizing cancer treatment, hopes to catch up by focusing on the next wave of immune system-boosting medicines. Setting out its research objectives in slides for a press conference on Wednesday, it said it aimed for "a leadership position in oncology" by...